Literature DB >> 6563942

Role of histamine in the antitumour activity of endotoxin.

N Bloksma, P van de Wiel, F Hofhuis, F Kuper, J Willers.   

Abstract

The role of histamine in the antitumour activity of endotoxin against solid syngeneic Meth-A sarcoma in BALB/c mice was studied. Endotoxin induces haemorrhagic necrosis and regression of this tumour. Histamine and the selective H1 receptor agonist 2-pyridylethylamine mimicked the induction of necrosis but did not cause regression. The selective H2 receptor agonist dimaprit did not cause any tumour damage. The effect of histamine could be inhibited by the H1 receptor antagonists diphenhydramine and promethazine but not by the H2 receptor antagonist cimetidine. Endotoxin-induced necrosis was slightly affected by diphenhydramine, and the incidence of regression was reduced by both H1 antagonists. Cimetidine potentiated endotoxin-induced regression. Similar effects were observed concerning the effects of H-receptor antagonists on necrosis and regression induced by tumour necrosis serum (TNS). Histological examination revealed no marked additional effects of diphenhydramine or cimetidine on endotoxin-induced hyperaemia, haemorrhagic necrosis, and mitotic arrest of the tumour cells. Only cimetidine increased the extent of nonhaemorrhagic necrosis. The endotoxin-induced release of tumour necrosis factor and cytostatic activity in TNS was clearly reduced by diphenhydramine, but hardly affected by cimetidine. Data indicate that intact H1 receptors are required for the induction of tumour regression and antitumour factors by endotoxin. Concomitant H2 blockade may facilitate this by stimulating H1 receptor-mediated processes upon endotoxin-induced histamine release, although a cimetidine-induced inhibition of T-suppressor cell activation might also be involved.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6563942     DOI: 10.1007/bf00205494

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  21 in total

1.  Rapid appearance of histamine hypersensitivity in mice by minute dose of endotoxins.

Authors:  K Kuratsuka; R Homma; Y Shimazaki; I Funasaka
Journal:  Experientia       Date:  1975-02-15

Review 2.  Bacterial endotoxins and host immune responses.

Authors:  D C Morrison; J L Ryan
Journal:  Adv Immunol       Date:  1979       Impact factor: 3.543

3.  Simultaneous induction of histidine and ornithine decarboxylases and changes in their product amines following the injection of Escherichia coli lipopolysaccharide into mice.

Authors:  Y Endo
Journal:  Biochem Pharmacol       Date:  1982-04-15       Impact factor: 5.858

4.  The influence of intraperitoneal injections of histamine on tumour growth in fibrosarcoma-bearing mice.

Authors:  C Burtin; P Scheinmann; J C Salomon; G Lespinats; F Loisillier; P Canu
Journal:  Cancer Lett       Date:  1981-04       Impact factor: 8.679

5.  Endotoxin-induced release of tumour necrosis factor and interferon in vivo is inhibited by prior adrenoceptor blockade.

Authors:  N Bloksma; F Hofhuis; B Benaissa-Trouw; J Willers
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

6.  The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity.

Authors:  M J Berendt; R J North; D P Kirstein
Journal:  J Exp Med       Date:  1978-12-01       Impact factor: 14.307

7.  Cimetidine amplifies the anti-neoplastic effect of Trichinella spiralis in mice.

Authors:  E J Ruitenberg; W Kruizinga; P A Steerenberg; A Elgersma; W H De Jong
Journal:  Br J Cancer       Date:  1982-02       Impact factor: 7.640

8.  Cimetidine and therapy of rodent tumours.

Authors:  D Hannant; K James; R E Bolton; M D Robertson; I Milne
Journal:  Br J Cancer       Date:  1982-04       Impact factor: 7.640

9.  Decrease in tumour growth by injections of histamine or serotonin in fibrosarcoma-bearing mice: influence of H1 and H2 histamine receptors.

Authors:  C Burtin; P Scheinmann; J C Salomon; G Lespinats; P Canu
Journal:  Br J Cancer       Date:  1982-01       Impact factor: 7.640

10.  Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA.

Authors:  I Parr; E Wheeler; P Alexander
Journal:  Br J Cancer       Date:  1973-05       Impact factor: 7.640

View more
  7 in total

1.  Translationally controlled tumor protein is a target of tumor reversion.

Authors:  Marcel Tuynder; Giusy Fiucci; Sylvie Prieur; Alexandra Lespagnol; Anne Géant; Séverine Beaucourt; Dominique Duflaut; Stéphanie Besse; Laurent Susini; Jean Cavarelli; Dino Moras; Robert Amson; Adam Telerman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-15       Impact factor: 11.205

2.  Synergic action between tumor necrosis factor and endotoxins or poly(A.U) on cultured bovine endothelial cells.

Authors:  P A van de Wiel; R H Pieters; A van der Pijl; N Bloksma
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Muramyl dipeptide is a powerful potentiator of the antitumor action of various tumor-necrotizing agents.

Authors:  N Bloksma; F M Hofhuis; J M Willers
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

4.  Macrophage infiltration in tumors and tumor-surrounding tissue: influence of serotonin and sensitized lymphocytes.

Authors:  G Los; R A De Weger; D T Van den Berg; R Sakkers; W Den Otter
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

5.  Endotoxin-mediated necrosis and regression of established tumours in the mouse. A correlative study of quantitative changes in blood flow and ultrastructural morphology.

Authors:  G G MacPherson; R J North
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

6.  Blood histamine and solid malignant tumors.

Authors:  C M Moriarty; J L Stucky; K W Hamburger; K D Patil; J F Foley; R R Koefoot
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

7.  Interaction of antihistaminic drugs with human translationally controlled tumor protein (TCTP) as novel approach for differentiation therapy.

Authors:  Ean-Jeong Seo; Thomas Efferth
Journal:  Oncotarget       Date:  2016-03-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.